A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats Hypertension Research 39, 415 (June 2016). doi:10.1038/hr.2016.2 Authors: Yui Takeshige, Yoshihide Fujisawa, Asadur Rahman, Wararat Kittikulsuth, Daisuke Nakano, Hirohito Mori, Tsutomu Masaki, Koji Ohmori, Masakazu Kohno, Hiroaki Ogata & Akira Nishiyama
Source: Hypertension Research - Category: Cardiology Authors: Tags: circadian blood pressure empagliflozin obese sodium-glucose co-transporter 2 (SGLT2) urinary sodium excretion Source Type: research